| Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. | None |
| Within-gene interaction between c.135 G/A genotypes and RET proto-oncogene germline mutations in HSCR families. | None |
| Single nucleotide polymorphic alleles in the 5 region of the RET proto-oncogene define a risk haplotype in Hirschsprung s disease. | None |
| The ret oncogene can induce melanogenesis and melanocyte development in Wv/Wv mice. | None |
| [Association of deletions of the RET proto-oncogene wtih aggressive course of sporatic C-cell carcinoma]. | None |
| Detection of mutations in RET proto-oncogene codon 634 through double tandem hybridization. | None |
| [The mutation character of the RET proto-oncogene in Chinese patients with Hirschsprung s disease]. | None |
| Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). | None |
| Loss-of-function germline mutations of the RET proto-oncogene are reported in familial and sporadic cases of Hirschsprung disease (HSCR) with a variable frequency | None |
| Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. | None |
| Shp-1 and Shp-2 are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes | None |
| The RET proto-oncogene: a potential target for molecular cancer therapy. | None |
| the RET proto-oncogene mutation Y791F, characterized by a low penetrance, occurs comparatively frequently among patients with normal serum calcitonin concentrations | None |
| Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. | None |
| Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. | None |
| Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G>A alleles modifying MEN 2A or HSCR phenotypes. | None |
| mechanisms leading to RET oncogenic conversion | None |
| Description of the first two seemingly unrelated Greek Cypriot families with a common C618R RET proto-oncogene mutation. | None |
| Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2. | None |
| Germ-Line Mutation in RET proto-oncogene is associated with Multiple Endocrine Neoplasia | None |